| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1000896133 |
| P356 | DOI | 10.1007/S00268-002-6612-1 |
| P698 | PubMed publication ID | 12016468 |
| P2093 | author name string | Eric J Bergstralh | |
| Ann L Oberg | |||
| Clive S Grant | |||
| Geoffrey B Thompson | |||
| Jon A van Heerden | |||
| Bryan McIver | |||
| Ian D Hay | |||
| Brian P Mullan | |||
| Colum A Gorman | |||
| John R Goellner | |||
| Claudia C Powell | |||
| Catherine E Dvorak | |||
| Megan S Maurer | |||
| P433 | issue | 8 | |
| P921 | main subject | patient | Q181600 |
| papillary thyroid cancer | Q2292945 | ||
| P304 | page(s) | 879-885 | |
| P577 | publication date | 2002-05-21 | |
| P1433 | published in | World Journal of Surgery | Q15763279 |
| P1476 | title | Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients | |
| P478 | volume | 26 |
| Q30367068 | 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer |
| Q33427321 | A Phase 1, Multi-Center, Open-Label, Dose-Escalation Study of 131I-CLR1404 in Subjects with Relapsed or Refractory Advanced Solid Malignancies |
| Q35760244 | A cross-specialty survey to assess the application of risk stratified surgery for differentiated thyroid cancer in the UK. |
| Q35558293 | A detailed clinicopathologic study of ALK-translocated papillary thyroid carcinoma |
| Q37725502 | A novel integrative risk index of papillary thyroid cancer progression combining genomic alterations and clinical factors |
| Q58786032 | AP-2α expression in papillary thyroid carcinoma predicts tumor progression and poor prognosis |
| Q85436847 | Adequacy of pathology reports of specimens from patients with differentiated thyroid cancer |
| Q88527369 | Adjuvant post-operative I-131 therapy in differentiated thyroid carcinoma: are the 2015 ATA guidelines an exact science or a dark art? |
| Q35441834 | Adjuvant radioactive iodine therapy is associated with improved survival for patients with intermediate-risk papillary thyroid cancer |
| Q37921604 | Advances in surgical therapy for thyroid cancer |
| Q33685745 | Aggressiveness of the tall cell variant of papillary thyroid carcinoma is independent of the tumor size and patient age. |
| Q42112455 | Amyloid precursor protein as a potential marker of malignancy and prognosis in papillary thyroid carcinoma |
| Q36586940 | An unexpected finding in the resection specimen of a carcinoma of the oral cavity: A case report |
| Q64321855 | Analysis of Survival and of Time Until Recurrence of Disease of Patients With Papillary Thyroid Carcinoma-Multivariant Analysis |
| Q37722349 | Annual financial impact of well-differentiated thyroid cancer care in the United States |
| Q38783065 | Anti-thyroglobulin antibodies do not significantly increase the risk of finding iodine avid metastases on post-radioactive iodine ablation scan in low-risk thyroid cancer patients. |
| Q51718288 | Application of post-surgical stimulated thyroglobulin for radioiodine remnant ablation selection in low-risk papillary thyroid carcinoma. |
| Q35908104 | Association between BRAF and RAS mutations, and RET rearrangements and the clinical features of papillary thyroid cancer |
| Q40134908 | Association of the oncostatin m receptor gene polymorphisms with papillary thyroid cancer in the korean population |
| Q34502078 | Autoantibody against WD repeat domain 1 is a novel serological biomarker for screening of thyroid neoplasia |
| Q34103836 | BRAF V600E in papillary thyroid carcinoma is associated with increased programmed death ligand 1 expression and suppressive immune cell infiltration. |
| Q54314073 | BRAF V600E mutation does not predict recurrence after long-term follow-up in TNM stage I or II papillary thyroid carcinoma patients. |
| Q38039906 | BRAF V600E mutation independently predicts central compartment lymph node metastasis in patients with papillary thyroid cancer |
| Q53077419 | BRAFwild papillary thyroid carcinoma has two distinct mRNA expression patterns with different clinical behaviors. |
| Q38645033 | Birth rates after radioactive iodine treatment for differentiated thyroid cancer |
| Q27851648 | Both BRAF V600E mutation and older age (≥ 65 years) are associated with recurrent papillary thyroid cancer |
| Q48108899 | Brain metastases from papillary thyroid carcinomas |
| Q60312782 | CLDN10 is Associated with Papillary Thyroid Cancer Progression |
| Q55374856 | Carbon nanoparticles guide contralateral central neck dissection in patients with papillary thyroid cancer. |
| Q82363907 | Central lymph node metastasis: is it a reliable indicator of lateral node involvement in papillary thyroid carcinoma? |
| Q79113259 | Changes in Clinical Presentation, Management and Outcome in 1348 Patients with Differentiated Thyroid Carcinoma: Experience in a Single Institute in Hong Kong, 1960–2000 |
| Q37015290 | Changing management in patients with papillary thyroid cancer |
| Q36817229 | Clinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastases. |
| Q36949784 | Clinical prognosis in BRAF-mutated PTC. |
| Q37381669 | Clustering of sebaceous gland carcinoma, papillary thyroid carcinoma and breast cancer in a woman as a new cancer susceptibility disorder: a case report |
| Q53618465 | Comparative effectiveness in thyroid cancer: key questions and how to answer them. |
| Q53375104 | Concomitant high expression of BRAFV600E, P-cadherin and cadherin 6 is associated with High TNM stage and lymph node metastasis in conventional papillary thyroid carcinoma. |
| Q63346832 | Consenso europeo para el tratamiento de los pacientes con carcinoma tiroideo diferenciado del epitelio folicular |
| Q30387260 | Conservative management of well-differentiated thyroid cancer |
| Q44018872 | Contrast-enhanced ultrasonography features of papillary thyroid carcinoma for predicting cervical lymph node metastasis |
| Q87369993 | Contrast-enhanced ultrasound (CEUS) facilitated US in detecting lateral neck lymph node metastasis of thyroid cancer patients: diagnosis value and enhancement patterns of malignant lymph nodes |
| Q36262288 | Controversies and challenges in the management of well-differentiated thyroid cancer. |
| Q38716870 | Controversies in the Management of Low-Risk Differentiated Thyroid Cancer |
| Q33677589 | Current concepts and future directions in differentiated thyroid cancer |
| Q28290814 | Current strategies for surgical management and adjuvant treatment of childhood papillary thyroid carcinoma |
| Q37976067 | Current surgical status of thyroid diseases. |
| Q89585393 | Diagnostic accuracy of single-source dual-energy computed tomography and ultrasonography for detection of lateral cervical lymph node metastases of papillary thyroid carcinoma |
| Q57279912 | Differentiated thyroid cancer theranostics: radioiodine and beyond |
| Q92514178 | Efficacy of posttreatment radioiodine scanning in patients with differentiated thyroid cancer |
| Q38088683 | Elective central compartment neck dissection in patients with papillary thyroid carcinoma recurrence |
| Q33345373 | Endoscopic tumor ablation for laryngotracheal intraluminal invasion secondary to advanced thyroid cancer |
| Q99364849 | Exosomal lncRNA DOCK9-AS2 derived from cancer stem cell-like cells activated Wnt/β-catenin pathway to aggravate stemness, proliferation, migration, and invasion in papillary thyroid carcinoma |
| Q38876768 | Experience and analysis of level VII cervical lymph node metastases in patients with papillary thyroid carcinoma |
| Q37188727 | Exploiting biology in selecting treatment for differentiated cancer of the thyroid gland. |
| Q54234351 | Expression of TGF-β1, SNAI1 and MMP-9 is associated with lymph node metastasis in papillary thyroid carcinoma. |
| Q88125770 | Extent of Thyroidectomy in Differentiated Thyroid Cancers-Review of Evidence |
| Q37854514 | Features of papillary thyroid carcinoma in patients older than 75 years |
| Q40161746 | Financial Implication of Radioactive Iodine Therapy for Early-Stage Papillary Thyroid Cancer. |
| Q38336451 | Frequent screening with serial neck ultrasound is more likely to identify false-positive abnormalities than clinically significant disease in the surveillance of intermediate risk papillary thyroid cancer patients without suspicious findings on foll |
| Q95271447 | GADD45B Transcript Is a Prognostic Marker in Papillary Thyroid Carcinoma Patients Treated With Total Thyroidectomy and Radioiodine Therapy |
| Q81337271 | Gamma probe-guided surgery for revision thyroidectomy: in comparison with conventional technique |
| Q36429534 | Gene-expression profiling in differentiated thyroid cancer--a viable strategy for the practice of genomic medicine? |
| Q26765085 | Genetic Testing in Differentiated Thyroid Carcinoma: Indications and Clinical Implications |
| Q36107776 | Geriatric thyroidology: An update |
| Q57482620 | Guidelines for radioiodine therapy of differentiated thyroid cancer |
| Q36774510 | Hemithyroidectomy increases the risk of disease recurrence in patients with ipsilateral multifocal papillary thyroid carcinoma |
| Q33713817 | Hobnail variant of papillary thyroid carcinoma: an institutional case series and molecular profile |
| Q37118811 | I-131 for Remnant Ablation in Differentiated Thyroid Cancer After Thyroidectomy: A Meta-Analysis of Randomized Controlled Evidence. |
| Q58555420 | Identification of key genes and miRNAs markers of papillary thyroid cancer |
| Q91660003 | Identifying risk factors of recurrence for clinically node negative papillary thyroid carcinoma with pathologic N1a |
| Q53833063 | Immunohistochemical Expression of TGF-Β1, SMAD4, SMAD7, TGFβRII and CD68-Positive TAM Densities in Papillary Thyroid Cancer. |
| Q93082159 | Impact of BMI on Complications and Satisfaction in Patients With Papillary Thyroid Cancer and Lateral Neck Metastasis |
| Q44819667 | Impact of early vs late postoperative radioiodine remnant ablation on final outcome in patients with low-risk well-differentiated thyroid cancer |
| Q86446620 | Impact of reclassifying noninvasive follicular variant of papillary thyroid carcinoma on the risk of malignancy in The Bethesda System for Reporting Thyroid Cytopathology |
| Q37309301 | Impact of surgical treatment on outcomes for papillary thyroid cancer |
| Q37628964 | Increased expression of EHF contributes to thyroid tumorigenesis through transcriptionally regulating HER2 and HER3. |
| Q38914373 | Indications for radioiodine administration in follicular-derived thyroid cancer |
| Q43719871 | Influence of age and primary tumor size on the risk for residual/recurrent well-differentiated thyroid carcinoma |
| Q37140715 | Influence of the thyroid remnant in the elevation of the serum thyroglobulin after thyroidectomy in differentiated thyroid carcinoma. Importance of the diagnostic iodine total-body scanning |
| Q37869194 | Initial therapy with either thyroid lobectomy or total thyroidectomy without radioactive iodine remnant ablation is associated with very low rates of structural disease recurrence in properly selected patients with differentiated thyroid cancer |
| Q28251986 | Integrated genomic characterization of papillary thyroid carcinoma |
| Q36463600 | Invasive well-differentiated thyroid carcinoma: effect of treatment modalities on outcome |
| Q64069205 | Investigation of the clonal origin of multifocal papillary thyroid carcinoma according to the X‑chromosome inactivation pattern |
| Q37165535 | Is routine central neck dissection necessary for the treatment of papillary thyroid microcarcinoma? |
| Q99557814 | Late recurrence of a papillary thyroid carcinoma 37 years after hemithyroidectomy: Solitary, left cervical lymph node metastasis evident on fluorodeoxyglucose positron-emission tomography/computed tomography images revealing nodular uptake |
| Q64066644 | LncRNA FOXD2-AS1 Functions as a Competing Endogenous RNA to Regulate TERT Expression by Sponging miR-7-5p in Thyroid Cancer |
| Q47733185 | Locoregional control of recurrent papillary thyroid carcinoma by ultrasound-guided percutaneous microwave ablation: A prospective study |
| Q92602332 | Long noncoding RNA ABHD11-AS1 functions as a competing endogenous RNA to regulate papillary thyroid cancer progression by miR-199a-5p/SLC1A5 axis |
| Q91683125 | Long noncoding RNA RP11-547D24.1 regulates proliferation and migration in papillary thyroid carcinoma: Identification and validation of a novel long noncoding RNA through integrated analysis of TCGA database |
| Q35857918 | Long-Term Follow-Up of the Therapeutic Outcomes for Papillary Thyroid Carcinoma With Distant Metastasis. |
| Q61812438 | Long-Term Outcome after Hemithyroidectomy for Papillary Thyroid Cancer: A Comparative Study and Review of the Literature |
| Q33570297 | Long-Term Outcomes Following Therapy in Differentiated Thyroid Carcinoma: NTCTCS Registry Analysis 1987-2012 |
| Q82576853 | Long-term outcome in 215 children and adolescents with papillary thyroid cancer treated during 1940 through 2008 |
| Q34615021 | MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro |
| Q30449566 | Malignant thyroid bed mass after total thyroidectomy |
| Q41912985 | Management of Invasive Differentiated Thyroid Cancer. |
| Q38182494 | Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement |
| Q84964097 | Management of thyroid cancer in Spain |
| Q36260094 | Management of thyroid carcinoma-an experience in Bangladesh |
| Q92276968 | MiR-509-5p improves the proliferative and invasive abilities of papillary thyroid carcinoma cells by inhibiting SFRP1 |
| Q53493497 | MiR-9 and miR-21 as prognostic biomarkers for recurrence in papillary thyroid cancer. |
| Q49335127 | MicroRNA-144 inhibits proliferation by targeting WW domain-containing transcription regulator protein 1 in papillary thyroid cancer |
| Q90347392 | Modern surgery for advanced thyroid cancer: a tailored approach |
| Q92188430 | Molecular Predictors for Advanced Papillary Thyroid Carcinoma Recurrence |
| Q37894309 | Molecular nuclear therapies for thyroid carcinoma |
| Q87782694 | Morbidity of central neck dissection: primary surgery vs reoperation. Results of a case-control study |
| Q38165028 | Multifocal papillary thyroid carcinoma--a consensus report of the European Society of Endocrine Surgeons (ESES). |
| Q34660901 | Multikinase inhibitors use in differentiated thyroid carcinoma. |
| Q52668584 | NEAT1_2 functions as a competing endogenous RNA to regulate ATAD2 expression by sponging microRNA-106b-5p in papillary thyroid cancer. |
| Q82556137 | New prognostic scales LAST-1 and LAST-2: supporting prediction and staging of thyroid cancer |
| Q36724334 | New therapeutic approaches for metastatic thyroid carcinoma |
| Q37859611 | New treatments and shifting paradigms in differentiated thyroid cancer management |
| Q37452292 | Overexpression of HIF-1α, metallothionein and SLUG is associated with high TNM stage and lymph node metastasis in papillary thyroid carcinoma |
| Q37316173 | Overexpression of HIF-2α, TWIST, and CXCR4 is associated with lymph node metastasis in papillary thyroid carcinoma |
| Q36282408 | Overexpression of NOTCH-regulated Ankyrin Repeat Protein is associated with papillary thyroid carcinoma progression |
| Q91846504 | PD-L1 and thyroid cytology: A possible diagnostic and prognostic marker |
| Q50067340 | Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015). |
| Q73589651 | Papillary microcarcinoma of the thyroid-Prognostic significance of lymph node metastasis and multifocality |
| Q42374161 | Papillary thyroid cancer recurrence 43 Years following Total Thyroidectomy and radioactive iodine ablation: a case report |
| Q47969500 | Partial Thyroidectomy for Papillary Thyroid Microcarcinoma: Is Completion Total Thyroidectomy Indicated? |
| Q39179386 | Patterns, predictive factors and prognostic impact of multilevel metastasis in N1b papillary thyroid carcinoma |
| Q41009215 | Pediatric papillary thyroid carcinoma: outcomes and survival predictors in 2504 surgical patients. |
| Q35152674 | Postoperative management of differentiated thyroid cancer |
| Q83239289 | Posttherapeutic (131)I SPECT-CT offers high diagnostic accuracy when the findings on conventional planar imaging are inconclusive and allows a tailored patient treatment regimen |
| Q34698065 | Prediction of extrathyroidal extension using ultrasonography and computed tomography. |
| Q38021435 | Predictive value of metastatic cervical lymph node ratio in papillary thyroid carcinoma recurrence |
| Q38513345 | Predictors of incomplete response to therapy among Filipino patients with papillary thyroid cancer in a tertiary hospital. |
| Q35440774 | Preoperative imaging modalities to predict the risk of regional nodal recurrence in well-differentiated thyroid cancers |
| Q80874182 | Preoperative neck ultrasonographic mapping for persistent/recurrent papillary thyroid cancer |
| Q37468257 | Prognosis of papillary thyroid carcinoma in elderly patients after thyroid resection: A retrospective cohort analysis |
| Q37921959 | Prognosis of patients with thyroid cancer who do not undergo surgical treatment: a SEER database analysis |
| Q38184374 | Prognostic biomarkers in thyroid cancer |
| Q36266372 | Prognostic factors and the effect of treatment with radioactive iodine and external beam radiation on patients with differentiated thyroid cancer seen at a single institution over 40 years. |
| Q39398365 | Prognostic factors for recurrence of locally advanced differentiated thyroid cancer. |
| Q73031829 | Prognostic factors in patients with Hürthle cell neoplasms of the thyroid |
| Q37388298 | Prognostic factors in patients with multiple recurrences of well-differentiated thyroid carcinoma. |
| Q89152568 | Prognostic role of the Bethesda System for conventional papillary thyroid carcinoma |
| Q82465296 | Prognostic significance of Tiam1 expression in papillary thyroid carcinoma |
| Q43981406 | Prognostic significance of USP22 as an oncogene in papillary thyroid carcinoma |
| Q54224425 | Prognostic significance of pituitary tumour-transforming gene-binding factor (PBF) expression in papillary thyroid carcinoma. |
| Q45853721 | Prognostic value of epidermal growth factor receptor, p53 and galectin-3 expression in papillary thyroid carcinoma |
| Q42285779 | Progress in Endocrine Neoplasia |
| Q64084348 | Promoter Hypomethylation as Recurrence Predictive Marker in Well-Differentiated Thyroid Carcinomas |
| Q97524393 | Proto-oncogene RTL4 promotes tumorigenesis and invasiveness of papillary thyroid cancer |
| Q27026163 | RAS mutations in thyroid cancer |
| Q39556707 | Radioactive iodine ablation does not prevent recurrences in patients with papillary thyroid microcarcinoma |
| Q53528184 | Radiofrequency ablation and percutaneous ethanol injection treatment for recurrent local and distant well-differentiated thyroid carcinoma. |
| Q47164528 | Radioiodine Ablation following Thyroidectomy for Differentiated Thyroid Cancer: Literature Review of Utility, Dose, and Toxicity. |
| Q37913996 | Radioiodine for remnant ablation and therapy of metastatic disease |
| Q36666666 | Re-operative neck surgery for well-differentiated thyroid cancer of follicular origin |
| Q51272259 | Recent advances in the surgical treatment of differentiated thyroid cancer: a comprehensive review. |
| Q30571649 | Recurrence rate in regional lymph nodes in 737 patients with follicular or Hürthle cell neoplasms |
| Q37624102 | Relationship of Focally Amplified Long Noncoding on Chromosome 1 (FAL1) lncRNA with E2F Transcription Factors in Thyroid Cancer |
| Q36615022 | Reproducibility of whole-body 131I scan and serum thyrotropin and stimulated thyroglobulin values in patients studied twice after injection of recombinant human thyrotropin |
| Q34918474 | Reproductive outcomes and nononcologic complications after radioactive iodine ablation for well-differentiated thyroid cancer |
| Q35163702 | Rising incidence of second cancers in patients with low-risk (T1N0) thyroid cancer who receive radioactive iodine therapy |
| Q37585292 | Risk factors associated with high thyroglobulin level following radioactive iodine ablation, measured 12 months after treatment for papillary thyroid carcinoma. |
| Q95262500 | Risk model and risk stratification to preoperatively predict central lymph node metastasis in papillary thyroid carcinoma |
| Q92647283 | Risk of needing completion thyroidectomy for low-risk papillary thyroid cancers treated by lobectomy |
| Q82250451 | Risks and adequacy of an optimized surgical approach to the primary surgical management of papillary thyroid carcinoma treated during 1999-2006 |
| Q36240455 | Role of Recombinant Human Thyrotropin (rhTSH) in the Treatment of Well-Differentiated Thyroid Cancer |
| Q94332426 | Role of preoperative ultrasonography in the surgical management of patients with thyroid cancer |
| Q34027466 | S100-A10, thioredoxin, and S100-A6 as biomarkers of papillary thyroid carcinoma with lymph node metastasis identified by MALDI imaging. |
| Q36666691 | Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma |
| Q53286133 | Shear wave elastography in evaluation of cervical lymph node metastasis of papillary thyroid carcinoma: elasticity index as a prognostic implication. |
| Q86500179 | Should patients with remnants from thyroid microcarcinoma really not be treated with iodine-131 ablation? |
| Q28266858 | Significance of the Extracapsular Spread of Metastatic Lymph Nodes in Papillary Thyroid Carcinoma |
| Q93035121 | Simultaneous tracheal and esophageal reconstruction for thyroid cancer involving trachea and esophagus using a free bipaddled posterior tibial artery perforator flap |
| Q45012482 | Sorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PET. |
| Q84784137 | Staging of Differentiated Thyroid Carcinoma Using Diagnostic 131I SPECT/CT |
| Q48699422 | Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level |
| Q39239856 | Surgical management of papillary thyroid carcinoma: an overview |
| Q64234248 | TGF-β1 promotes the invasion and migration of papillary thyroid carcinoma cells by inhibiting the expression of lncRNA-NEF |
| Q100385793 | TRIM29 inhibits miR-873-5P biogenesis via CYTOR to upregulate fibronectin 1 and promotes invasion of papillary thyroid cancer cells |
| Q47659279 | Temporal analysis of thyroid cancer management in a Melbourne tertiary centre. |
| Q37808222 | The Effectiveness of Radioactive Iodine for Treatment of Low-Risk Thyroid Cancer: A Systematic Analysis of the Peer-Reviewed Literature from 1966 to April 2008 |
| Q90284138 | The Expression of Tumor-Associated Macrophages and Multinucleated Giant Cells in Papillary Thyroid Carcinoma |
| Q38743211 | The Prognostic Value of Tumor Multifocality in Clinical Outcomes of Papillary Thyroid Cancer |
| Q79190406 | The advantage of near-total thyroidectomy to avoid postoperative hypoparathyroidism in benign multinodular goiter |
| Q42579889 | The contributions of gamma probe to lesion detectability and surgical safety in recurrent thyroid cancer at risk. |
| Q46605690 | The early treatment results of well differentiated thyroid cancer and its dependence on chosen factors |
| Q35121406 | The expression of twist in differentiated thyroid carcinomas |
| Q33973108 | The pros and cons of prophylactic central neck dissection in papillary thyroid carcinoma. |
| Q38603131 | The role of prophylactic central neck dissection in differentiated thyroid carcinoma: issues and controversies. |
| Q33648181 | The thyroid cancer policy model: A mathematical simulation model of papillary thyroid carcinoma in The U.S. population |
| Q47443855 | The utility of intra-operative frozen section for the evaluation of microscopic extrathyroidal extension in papillary thyroid carcinoma |
| Q36725764 | Thyroid Remnant Estimation by Diagnostic Dose (131)I Scintigraphy or (99m)TcO4(-) Scintigraphy after Thyroidectomy: A Comparison with Therapeutic Dose (131)I Imaging. |
| Q34821078 | Thyroid cancer: burden of illness and management of disease |
| Q26748491 | Thyroid computed tomography imaging: pictorial review of variable pathologies |
| Q89703942 | Total thyroidectomy versus thyroid lobectomy in the treatment of papillary carcinoma |
| Q84723737 | Treatment and follow-up of low-risk patients with thyroid cancer |
| Q92015279 | Treatment for benign thyroid nodules with a combination of natural extracts |
| Q53726666 | Treatment patterns of aging Americans with differentiated thyroid cancer. |
| Q47135233 | Tumor-suppressive function of UNC5D in papillary thyroid cancer |
| Q92108295 | US-Guided Radiofrequency Ablation for Low-Risk Papillary Thyroid Microcarcinoma: Efficacy and Safety in a Large Population |
| Q37910198 | Ultrasonographically detected small thyroid bed nodules identified after total thyroidectomy for differentiated thyroid cancer seldom show clinically significant structural progression. |
| Q38011123 | Ultrasound-guided fine-needle aspiration biopsy of thyroid bed lesions from patients with thyroidectomy for thyroid carcinomas |
| Q90452551 | Upregulation of lncRNA-ATB by Transforming Growth Factor β1 (TGF-β1) Promotes Migration and Invasion of Papillary Thyroid Carcinoma Cells |
| Q35961413 | Use of radioactive iodine for thyroid cancer |
| Q36377222 | Use of recombinant human thyroid-stimulating hormone in the management of well-differentiated thyroid cancer |
| Q38091402 | Utility of internal jugular vein reconstruction in modified radical neck dissection |
| Q38063414 | Well-differentiated thyroid carcinoma: the role of post-operative radioactive iodine administration. |
| Q26765080 | What is the Minimal Surgery for Papillary Thyroid Carcinoma? |
| Q53542966 | [Differenciated thyroid carcinomas with laryngo-tracheal invasion] |
| Q79780984 | [Pulmonary and brain metastases from well-differentiated thyroid carcinoma] |
| Q86591790 | [What's new in follicular thyroid cancer management in 2014?] |
| Q92345904 | miR-424-5p Promotes Anoikis Resistance and Lung Metastasis by Inactivating Hippo Signaling in Thyroid Cancer |
| Q38395979 | miR-451a is underexpressed and targets AKT/mTOR pathway in papillary thyroid carcinoma. |
Search more.